Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial.

ABSTRACT:

Background

Dapagliflozin and finerenone reduce albuminuria and slow CKD progression, but additive effects remain unstudied. We compared their individual and combined efficacy and safety in patients with non-diabetic CKD.

Methods

In an open-label, randomized clinical trial, we included patients aged 18-80 on maximal tolerated ACE inhibitor or angiotensin receptor blocker with eGFR 25-45 mL/min/1,73 m² and albuminuria 150-2000 mg/g. Participants received either finerenone 20 mg/day or dapagliflozin 10 mg/day for four weeks, followed by combination therapy for four weeks. Data were collected at baseline, 4 and 8 weeks.

Results

Twenty patients (10 per group) with a mean mGFR of 34 mL/min/1,73 m² and a mean urine albumin creatinine ratio (UACR) of 469

SUBMITTER: Marup FH 

PROVIDER: S-EPMC10768792 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature